Merck — The company is in final-stage testing for an intravenous treatment that would protect against C. diff bacteria for three months.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Sanofi — Sanofi is in mid-stage trials for a C. diff vaccine, which would be the only one on the market, if approved. The trials will conclude in 2018.
Actelion — The company is in late-stage testing of a new antibiotic to combat C. diff, cadazolid. It expects results in 2016.
Shire — As of March 2014, the company completed mid-stage safety and efficacy trials for its VP20621, acquired from ViroPharma in a takeover last year.
Cubist Pharmaceuticals — The company is in final-stage testing for the antibiotic surotomycin. It expects final data by 2015.
Synthetic Biologics — The company is entering mid-stage testing for its C. diff-preventing pill.
More Articles on Infection Control & Clinical Quality:
FDA Recommends 2 New Anti-MRSA Agents
Lucrative Treatments Overlooked For Lists of Unecessary Procedures
Direct Patient Education Improves Adherence to Drug-Use Guidelines
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.